U.S. Chemicals Stock News

Sleep Number (SNBR) has capped FY 2025 with fourth quarter revenue of US$347.4 million and a basic EPS loss of US$2.55, as net income excluding extra items came in at a loss of US$58.5 million. The company has seen quarterly revenue move from US$393.3 million in Q1 2025 to US$327.9 million in Q2, US$342.9 million in Q3 and US$347.4 million in Q4, alongside a widening basic EPS loss over the same stretch. For investors, that mix of steady sales levels and deeper losses keeps the focus firmly...

Frequency Electronics (FEIM) has just posted Q3 2026 results with revenue of US$16.9 million, basic EPS of US$0.16 and net income of US$1.6 million. This comes in a year where trailing 12 month revenue sits at US$67.8 million and EPS at US$0.74. Over recent quarters the company has seen revenue move from US$18.9 million in Q3 2025 to US$19.0 million in Q4 2025, then US$13.8 million, US$17.1 million and now US$16.9 million. Basic EPS shifted from US$1.60 to US$0.33, US$0.07, US$0.18 and...

Q32 Bio (QTTB) has just posted its FY 2025 numbers, reporting fourth quarter revenue of US$53.7 million and basic EPS of US$4.60, alongside trailing 12 month basic EPS of US$2.42 and net income of US$29.8 million. The company’s quarterly revenue has moved from US$0 and a basic EPS loss of US$1.16 in Q4 2024 to US$53.7 million and US$4.60 in Q4 2025. Interim 2025 quarters showed no revenue and basic EPS losses between US$0.60 and US$0.90, so investors will likely focus on how durable these...

Aemetis (AMTX) has wrapped up FY 2025 with Q4 revenue of US$53.7 million and a basic EPS loss of US$0.08, alongside trailing 12 month revenue of US$197.6 million and a cumulative net loss of US$77.0 million. Over recent quarters, the company has seen quarterly revenue move between US$42.9 million and US$59.2 million, while basic EPS losses ranged from US$0.47 to US$0.08. This latest print keeps the focus squarely on how quickly margins can tighten up from here. See our full analysis for...

Chicago Atlantic Real Estate Finance (REFI) has wrapped up FY 2025 with fourth quarter total revenue of US$14.1 million and basic EPS of US$0.39, giving investors fresh numbers to weigh against its high headline yield and recent margin trends. The company has seen quarterly revenue move between US$13.1 million and US$15.4 million over the last six reported periods, while basic EPS ranged from US$0.39 to US$0.57 over the same timeframe. This sets a clear frame of reference for the latest print...

LifeMD (LFMD) is back in focus after its latest earnings, where the telehealth provider reported full year 2025 net income of US$14.35 million and issued fresh 2026 revenue guidance. See our latest analysis for LifeMD. LifeMD’s latest earnings and 2026 guidance have arrived after a sharp recent move, with a 7 day share price return of 31.17% and a 30 day share price return of 29.02% despite a 1 year total shareholder return decline of 30.48%. Short term momentum is building, while the longer...

Bumble (BMBL) has returned to investor attention after Q4 2025 earnings topped expectations, first quarter 2026 revenue guidance of US$209 million to US$213 million, and the announcement of new AI driven product and platform plans. See our latest analysis for Bumble. The Q4 surprise and AI rollout have triggered a sharp shift in sentiment, with a 34.2% 1-day share price return and 21.7% 7-day share price return contrasting with a 1-year total shareholder return of negative 20%. This suggests...

Immersion (IMMR) has just posted its FY 2025 numbers with Q4 revenue of US$281.4 million and a basic EPS loss of US$0.17, capping off a year in which trailing twelve month revenue reached about US$1.6 billion and EPS came in at US$2.00. Over recent periods, the company has seen revenue move from US$163.1 million on a trailing basis in mid 2024 to about US$1.6 billion by FY 2025. Over the same timeframe, trailing EPS shifted from US$2.08 to US$2.00. Investors are left to weigh that scale of...

If you are wondering whether Q2 Holdings at around US$48.75 is a bargain or a value trap, you are not alone. This article is designed to help you frame that question clearly. The stock is currently around US$48.75, with returns of a 6.4% decline over 7 days, a 15.0% decline over 30 days, a 29.8% decline year to date and a 33.3% decline over 1 year, while the 3 year return is 100.5% and the 5 year return is a 53.8% decline. Recent attention on Q2 Holdings has centered on how its digital...

SNDL FY 2025 Results: Revenue Holds Steady While Losses Persist SNDL (NasdaqCM:SNDL) has just posted its latest numbers, with third quarter FY 2025 revenue at C$244.2 million and basic EPS at a loss of C$0.05, setting the tone for a year where profitability remains under pressure. The company has seen quarterly revenue move from C$257.7 million in Q4 2024 to C$204.9 million in Q1 2025, then sit around C$244 million through Q2 and Q3 2025, while EPS has swung between a loss of C$0.25 in Q4...

Latest FY 2025 results set the stage Navigator Holdings (NVGS) has capped FY 2025 with fourth quarter revenue of US$152.8 million and basic EPS of US$0.28, while the trailing twelve month figures show revenue of US$587.0 million and EPS of US$1.49, supported by net income of US$100.1 million. Over the past few individual quarters, revenue has ranged from US$129.6 million to just over US$153.1 million. Quarterly EPS has moved between US$0.26 and US$0.50, and investors will likely focus on how...

Codexis FY 2025 Results: Revenue Rebounds As Profitability Swings Positive In Q4 Codexis (CDXS) closed FY 2025 with a sharp Q4 reset, reporting US$38.9 million in revenue and basic EPS of US$0.11, alongside net income of US$9.6 million, against a trailing twelve month loss of US$44.0 million and a TTM basic EPS loss of US$0.50. The company has seen quarterly revenue move from US$21.5 million in Q4 2024 to US$7.5 million in Q1 2025, US$15.3 million in Q2 2025, US$8.6 million in Q3 2025, and...

Guardian Pharmacy Services (GRDN) has just wrapped up FY 2025 with Q4 revenue of US$397.6 million and basic EPS of US$0.33, alongside trailing 12 month revenue of about US$1.4 billion and EPS of US$0.79 as the business has moved into consistent profitability. The company has seen revenue lift from US$338.6 million and EPS of a US$0.17 loss in Q4 FY 2024 to US$397.6 million and EPS of US$0.33 in Q4 FY 2025, while trailing net income shifted from a US$110.0 million loss at FY 2024 year end to a...

Resolute Holdings Management (RHLD) has put out a mixed set of FY 2025 numbers, with Q3 revenue at US$120.9 million and a small net loss of US$0.2 million, translating to basic EPS of US$0.03 loss per share. Over recent quarters the company has seen revenue move from US$103.9 million in Q1 FY 2025 to US$119.6 million in Q2 and US$120.9 million in Q3. EPS shifted from a US$0.39 loss to a US$0.07 loss and then to a US$0.03 loss, setting the backdrop for investors who are watching how much of...

Stoneridge (SRI) has just reported third quarter FY 2025 results with revenue of US$210.3 million and a basic EPS loss of US$0.34, while net income excluding extra items was a loss of US$9.4 million. Over recent quarters, the company has seen revenue move between US$213.8 million and US$237.1 million with basic EPS ranging from a profit of US$0.10 to losses of roughly US$0.22 to US$0.34. The trailing twelve month figures show US$874.4 million of revenue paired with a net loss of US$32.0...

Kansas City Life Insurance (KCLI) has wrapped up FY 2025 with fourth quarter revenue of US$120.4 million, basic EPS of US$0.23 and net income of US$2.3 million, alongside trailing 12 month revenue of US$485.5 million and a net loss of US$20.8 million, which translates to basic EPS of a US$2.14 loss. Over recent quarters the company has seen revenue move between US$118.98 million and US$125.15 million, while quarterly EPS has ranged from a US$2.90 loss to a US$0.33 profit. This sets up a story...

Inland Real Estate Income Trust (INRE) has posted its FY 2025 numbers with Q4 total revenue of US$38.7 million and a basic EPS loss of US$0.12, alongside funds from operations of US$36.3 million in the red. This gives investors a mixed read on operating performance and cash generation. Over the past year, total revenue has held in a tight band around US$150 million on a trailing twelve month basis while basic EPS for the same period came in at a loss of US$0.31, underscoring a sustained loss...

Mistras Group (MG) just closed out FY 2025 with fourth quarter revenue of US$181.5 million and basic EPS of US$0.12, alongside trailing twelve month revenue of US$724.0 million and EPS of US$0.54 that were shaped by a reported net profit margin of 2.3%. Over recent periods, the company has seen quarterly revenue move from US$172.7 million in FY 2024 Q4 to US$195.5 million in FY 2025 Q3 before landing at US$181.5 million in FY 2025 Q4. Quarterly EPS ranged from a loss of US$0.10 in FY 2025 Q1...

TechTarget (TTGT) has just posted its FY 2025 numbers with Q4 revenue of US$140.7 million and a basic EPS loss of US$0.13, capping a trailing 12 month period that featured revenue of US$486.8 million and a basic EPS loss of US$14.06. Over recent quarters, the company has seen revenue move from US$99.9 million in Q4 FY 2024 to US$103.9 million in Q1 FY 2025, US$119.9 million in Q2, US$122.3 million in Q3 and US$140.7 million in Q4. Quarterly basic EPS losses shifted from US$0.90 to US$7.32,...

Sealed Air (NYSE:SEE) has announced its intention to redeem multiple senior notes, subject to the closing of a pending transaction. The planned redemptions would retire certain outstanding debt instruments once the transaction is completed. The company has outlined the expected redemption terms ahead of closing to give bondholders and shareholders clarity on next steps. For investors watching Sealed Air, the focus now is on how this conditional redemption plan fits with the company’s...

If you are wondering whether Amicus Therapeutics at around US$14.37 is attractively priced or already reflecting a lot of optimism, you are in the right place to focus on what the numbers are actually saying about value. The stock's return profile, with 0.3% over the last 7 days, 0.5% over 30 days, 0.7% year to date and 61.6% over 1 year, suggests the market has been reassessing the company over different time frames. Recent news around Amicus Therapeutics has continued to center on its role...

Centessa Pharmaceuticals recently reported past Phase II progress for its orexin agonist ORX750 in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia, highlighting clinically meaningful effects alongside a favorable safety and tolerability profile. The company also outlined plans for registrational studies in rare hypersomnias, expanded its open-label extension to four weeks, and began preparing for regulatory engagement and commercial build-out, underscoring how central ORX750...

Campbell's (CPB) has just reported its latest results with Q2 2026 revenue of US$2.68 billion and basic EPS of US$0.65, setting the tone for how the rest of the year may shape up. Looking back over recent quarters, revenue has moved between US$2.29 billion in Q4 2024 and US$2.77 billion in Q1 2025, while basic EPS has ranged from a small loss of US$0.01 in Q4 2024 to US$0.73 in Q1 2025. This gives investors a clear view of how sales and earnings have tracked into this quarter. With net income...

Conference spotlight and why AIRO is on more investor radars AIRO Group Holdings (AIRO) is set to present at the 2026 Cantor Global Technology & Industrial Growth Conference on March 11 in New York, giving investors a closer look at its aerospace and defense business. With Co Founder and Executive Chairman Chirinjeev Baboo Kathuria, Chief Executive Officer Joe Burns and Chief Financial Officer Mariya Pylypiv on stage, the session could offer more detail on AIRO’s drone, avionics, training and...